Uruguay is a small but stable, high-quality clinical research market. The Ministry of Public Health (MSP), through its General Directorate of Health (DIGESA), regulates clinical research; Decreto 158/019 governs studies involving human subjects; medical devices fall under Decree 3/008; and Uruguay is a MERCOSUR member. With ISO 14155 alignment and bioaccess®'s coordination, sponsors generate FDA-submissible data at ~30% lower cost than US/EU programs.
Uruguay is a small but stable, high-quality clinical research market in the MERCOSUR region. Its regulator is the Ministry of Public Health (MSP), acting through the General Directorate of Health (DIGESA). Research involving human subjects is governed by Decreto 158/019, which establishes a defined framework aligned with international ethics standards.
Under Decreto 158/019, the National Commission of Ethics in Research (Comisión Nacional de Ética en Investigación) reviews studies and sends its assessment to MSP's General Directorate of Health; in parallel, the institutional ethics committee of the research institution must approve protocols. Medical devices fall under Decree 3/008, and Uruguay's MERCOSUR membership provides regional regulatory alignment.
bioaccess® coordinates MSP/DIGESA interactions, National Commission of Ethics submissions, institutional ethics review, site qualification, and monitoring so sponsors get FDA-quality first-in-human data at roughly 30% lower cost than a comparable US or EU program. Uruguay is a strong option for sponsors valuing stability and quality.
Uruguay's Ministry of Public Health (MSP), through its General Directorate of Health (DIGESA), is the national authority overseeing clinical research. bioaccess® prepares complete regulatory dossiers and coordinates directly with MSP/DIGESA through study start-up.
Research involving human subjects in Uruguay is governed by Decreto 158/019. The National Commission of Ethics in Research (Comisión Nacional de Ética en Investigación) reviews studies and sends its assessment to MSP's General Directorate of Health. In parallel, the institutional ethics committee of the research institution must approve protocols. bioaccess® coordinates both ethics tracks.
Medical devices in Uruguay fall under Decree 3/008. As a MERCOSUR member, Uruguay's device framework is regionally aligned, which can facilitate multi-country strategies within the bloc. For FIH studies, sponsors also secure an investigational device import authorization under the MSP/DIGESA framework so product can be shipped into the country. bioaccess® integrates device-side requirements and the import authorization with the trial authorization pathway.
Under 21 CFR 812.28, foreign clinical data is eligible for FDA submission and review from Uruguay for IDE submissions and marketing applications when studies are conducted under ISO 14155 with proper MSP/DIGESA authorization and ethics approval. bioaccess® designs every protocol for FDA submission from day one.
| Metric | Uruguay 🇺🇾 | United States 🇺🇸 | Europe (EU) 🇪🇺 |
|---|---|---|---|
| Regulatory authority | MSP — DIGESA | FDA | EMA / national CAs |
| Ethics review | National Commission of Ethics (Decreto 158/019) + institutional EC | Local IRBs | Per-country ECs |
| Device framework | Decree 3/008; MERCOSUR-aligned | 21 CFR 812 | EU MDR |
| FDA data acceptance | Eligible for submission/review — 21 CFR 812.28 (ISO 14155) | Native | Yes, with justification |
| Cost vs. US program | ~30% lower | Baseline | ~15–25% lower |
| Time zone vs. US East Coast | +1 to +2 hours | Same | +5 to +6 hours |
Regulatory details reflect published national frameworks; timelines and costs vary by device complexity, therapeutic area, and monitoring requirements. bioaccess® confirms the current pathway for each program.
The Ministry of Public Health (MSP), through its General Directorate of Health (DIGESA), is Uruguay's national regulator for clinical research.
Research on human subjects is governed by Decreto 158/019. The National Commission of Ethics in Research reviews studies and sends its assessment to MSP's General Directorate of Health, and the institutional ethics committee of the research institution must also approve the protocol.
Medical devices in Uruguay fall under Decree 3/008, and Uruguay's MERCOSUR membership provides regional regulatory alignment.
Yes. Under 21 CFR 812.28, foreign clinical data is eligible for FDA submission and review from Uruguay when studies are conducted under ISO 14155 with proper MSP/DIGESA authorization and ethics approval. bioaccess® designs protocols for FDA submission from the start.
Uruguay programs typically run ~30% lower than a comparable US or EU program. Actual cost depends on device complexity, indication, monitoring intensity, and sample size — bioaccess® scopes each program individually.
Uruguay combines a defined MSP/DIGESA pathway, a clear ethics framework under Decreto 158/019, MERCOSUR-aligned device regulation, and ~30% lower program cost than US/EU baselines — making it a strong stability-and-quality choice.
All countries we serve · Contact bioaccess® · First-in-Human CRO